Stockscreener 앱 받기
8.05
2.78%
-0.23
시간 외 거래:
8.07
0.02
+0.25%
전일 마감가:
$8.28
열려 있는:
$8.27
하루 거래량:
203.27K
Relative Volume:
0.52
시가총액:
$419.22M
수익:
-
순이익/손실:
$-19.90M
주가수익비율:
-15.19
EPS:
-0.53
순현금흐름:
$-19.80M
1주 성능:
-3.59%
1개월 성능:
-6.72%
6개월 성능:
+109.64%
1년 성능:
+50.75%
1일 변동 폭
$7.95
$8.27
1주일 범위
$7.95
$8.58
52주 변동 폭
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
명칭
Diamedica Therapeutics Inc
전화
(763) 496-5454
주소
301 CARLSON PARKWAY, MINNEAPOLIS, MN
DMAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
8.05 | 431.20M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 개시 | TD Cowen | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-06-22 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 개시 | Oppenheimer | Outperform |
| 2021-02-17 | 개시 | ROTH Capital | Buy |
| 2020-10-30 | 개시 | Guggenheim | Buy |
| 2020-07-08 | 개시 | Maxim Group | Buy |
| 2019-04-30 | 개시 | Dougherty & Company | Buy |
| 2019-03-05 | 개시 | Lake Street | Buy |
모두보기
Diamedica Therapeutics Inc 주식(DMAC)의 최신 뉴스
DiaMedica Therapeutics (DMAC) price target increased by 25.68% to 15.81 - MSN
Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
DiaMedica Therapeutics provides DM199 update following FDA meeting - MSN
Why DiaMedica Therapeutics Inc. stock attracts high net worth investorsGold Moves & Low Volatility Stock Suggestions - Улправда
Is DiaMedica Therapeutics Inc. stock in correction or buying zone2025 Market Outlook & Free Low Drawdown Momentum Trade Ideas - Улправда
Aug Big Picture: Why DiaMedica Therapeutics Inc. stock is a value investor pickInsider Selling & Weekly Watchlist for Hot Stocks - Улправда
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
DiaMedica (DMAC) Advances with FDA in Preeclampsia Study Plans - GuruFocus
DiaMedica Says FDA Seeks Additional Study Ahead of Pre-IND Submission for Preeclampsia Treatment - marketscreener.com
DiaMedica to conduct additional study for preeclampsia treatment - Investing.com
DiaMedica to conduct additional study for preeclampsia treatment By Investing.com - Investing.com Canada
Diamedica Therapeutics provides DM199 preeclampsia program update - marketscreener.com
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting - TipRanks
DiaMedica Therapeutics Inc Provides DM199 Preeclampsia Program Update - TradingView — Track All Markets
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - The AI Journal
[8-K] DiaMedica Therapeutics Inc. Reports Material Event | DMAC SEC FilingForm 8-K - Stock Titan
A US$59m Drop in the Market Cap of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Is Not What Insiders Like to See After Purchasing Shares Recently - 富途牛牛
DiaMedica Therapeutics Earnings Notes - Trefis
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 7.4%Here's Why - MarketBeat
DiaMedica Therapeutics Inc (DMAC) Stock News & Articles - 24/7 Wall St.
Top investors say DiaMedica Therapeutics Inc (DMAC) ticks everything they need - setenews.com
DiaMedica Therapeutics (NASDAQ:DMAC) Sets New 1-Year HighTime to Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Purchases 182,882 Shares of Stock - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Buys 187,393 Shares of Stock - Defense World
Jan Stahlberg Acquires 208,872 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Acquires $1,234,453.50 in Stock - MarketBeat
Insider Buying: DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Purchases 128,426 Shares of Stock - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Purchases 40,253 Shares - MarketBeat
What dividend safety score for DiaMedica Therapeutics Inc. stock2025 Risk Factors & Fast Gain Stock Tips - Newser
What drives DiaMedica Therapeutics Inc stock priceAnalyst Downgrades & Free Lightning Fast Capital Gains - earlytimes.in
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth - Yahoo Finance
Private Capital's DiaMedica Therapeutics Inc(DMAC) Holding History - GuruFocus
Why DiaMedica Therapeutics Inc. stock is a value investor pickJuly 2025 Drop Watch & Smart Allocation Stock Tips - moha.gov.vn
There is no way DiaMedica Therapeutics Inc (DMAC) can keep these numbers up - setenews.com
Dir Parsons Acquires 12,000 Of DiaMedica Therapeutics Inc [DMAC] - TradingView
[Form 4] DiaMedica Therapeutics Inc. Insider Trading Activity - Stock Titan
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
DiaMedica In Focus After 52-Week High And FDA Meeting Progress - RTTNews
How DiaMedica Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double - inkl
HC Wainwright Has Bearish Forecast for DMAC FY2025 Earnings - Defense World
Smart tools for monitoring DiaMedica Therapeutics Inc.’s price actionPortfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Why analysts remain bullish on DiaMedica Therapeutics Inc. stock2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Published on: 2025-11-19 22:42:15 - newser.com
Diamedica Therapeutics Inc (DMAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
0.08%
자본화:
|
볼륨(24시간):